Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to $30.8 million.

  • Revolution Medicines' Share-based Compensation rose 4815.4% to $30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.1 million, marking a year-over-year increase of 3035.47%. This contributed to the annual value of $79.2 million for FY2024, which is 2820.86% up from last year.
  • Per Revolution Medicines' latest filing, its Share-based Compensation stood at $30.8 million for Q3 2025, which was up 4815.4% from $28.8 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Share-based Compensation peaked at $30.8 million during Q3 2025, and registered a low of $3.4 million during Q1 2021.
  • For the 5-year period, Revolution Medicines' Share-based Compensation averaged around $14.6 million, with its median value being $13.0 million (2023).
  • As far as peak fluctuations go, Revolution Medicines' Share-based Compensation skyrocketed by 20576.0% in 2023, and later plummeted by 1175.13% in 2024.
  • Quarter analysis of 5 years shows Revolution Medicines' Share-based Compensation stood at $6.2 million in 2021, then soared by 34.19% to $8.3 million in 2022, then skyrocketed by 205.76% to $25.4 million in 2023, then fell by 11.75% to $22.4 million in 2024, then soared by 37.17% to $30.8 million in 2025.
  • Its Share-based Compensation stands at $30.8 million for Q3 2025, versus $28.8 million for Q2 2025 and $25.1 million for Q1 2025.